{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:39:02Z","timestamp":1787841542760,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Osteoporosis poses a challenge to public health, causing fragility fractures, especially in postmenopausal women. Abaloparatide (ABL) is an effective anabolic agent to improve bone formation and resorption among postmenopausal women with osteoporosis. Our meta-analysis aims to assess the effectiveness and safety of ABL versus teriparatide (TPTD) in improving bone mineral density (BMD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched Medline, Embase, Web of Science, Cochrane databases and Clinicaltrial.gov until September 2, 2022. We included data from randomized controlled trials (RCTs) and post hoc analyses of RCTs. Outcomes included BMD change from baseline and risks of adverse events. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) tool was used to evaluate the quality of outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four studies including 16 subgroups were included in this study. In particular, RCTs with head-to-head comparisons of ABL and TPTD were used in the meta-analysis, and all were from manufacturer-sponsored trials. All parameters in 24\u00a0weeks except lumbar spine (versus TPTD) showed significant advantages in the ABL group. Only the results of two subgroups in ABL versus TPTD demonstrated <jats:italic>High<\/jats:italic> GRADE quality (femoral neck: weighted mean difference (WMD)\u2009=\u20091.58 [0.52, 2.63]; Total hip: WMD\u2009=\u20091.46 [0.59, 2.32]). However, our fracture data were insufficient. Besides, we found no evident difference in serious adverse events or deaths in either group and the incidence of hypercalcemia in the ABL group lessened by 51% compared with the TPTD group. Nevertheless, compared with placebo, ABL demonstrated higher risks of nausea and palpitations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ABL demonstrated a beneficial effect on BMD compared to both placebo and TPTD for postmenopausal women with osteoporosis. ABL also had insignificantly lowered adverse event risk than TPTD. ABL is an alternative for patients with postmenopausal osteoporosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13018-023-03595-x","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T05:07:32Z","timestamp":1676610452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Pan","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaJia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YeMing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0610-2991","authenticated-orcid":false,"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"10","key":"3595_CR1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/medicina57101119","volume":"57","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Giorgino R, Hildebrand F, Spiezia F, Peretti GM, Alessandri-Bonetti M, Eschweiler J, Maffulli N. Fragility fractures: risk factors and management in the elderly. Medicina. 2021;57(10):1119.","journal-title":"Medicina"},{"issue":"3","key":"3595_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254\u201362.","journal-title":"N Engl J Med"},{"issue":"5","key":"3595_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","volume":"104","author":"CB Johnston","year":"2020","unstructured":"Johnston CB, Dagar M. Osteoporosis in older adults. Med Clin North Am. 2020;104(5):873\u201384.","journal-title":"Med Clin North Am"},{"issue":"11","key":"3595_CR4","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520\u20136.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"3595_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1185\/03007995.2015.1037729","volume":"31","author":"L Si","year":"2015","unstructured":"Si L, Winzenberg TM, Chen M, et al. Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women. Curr Med Res Opin. 2015;31(6):1149\u201356.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"3595_CR6","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","volume":"30","author":"A Svedbom","year":"2019","unstructured":"Svedbom A, Hadji P, Hernlund E, et al. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporos Int. 2019;30(9):1745\u201354.","journal-title":"Osteoporos Int"},{"issue":"8","key":"3595_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.7326\/L21-0434","volume":"174","author":"A Qaseem","year":"2021","unstructured":"Qaseem A, Wilt TJ. Treatment of low bone density or osteoporosis to prevent fractures. Ann Intern Med. 2021;174(8):1191\u20132.","journal-title":"Ann Intern Med"},{"issue":"11","key":"3595_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea MA, McLean RM, et al. Clinical guidelines committee of the American college of physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American college of physicians. Ann Intern Med. 2017;166(11):818\u201339.","journal-title":"Ann Intern Med"},{"issue":"2\u20133","key":"3595_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1024\/0300-9831\/a000063","volume":"81","author":"JP Bonjour","year":"2011","unstructured":"Bonjour JP. Protein intake and bone health. Int J Vitam Nutr Res. 2011;81(2\u20133):134\u201342.","journal-title":"Int J Vitam Nutr Res"},{"issue":"2","key":"3595_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/nu13020525","volume":"13","author":"AE Ratajczak","year":"2021","unstructured":"Ratajczak AE, Rychter AM, Zawada A, et al. Do only calcium and vitamin D matter? Micronutrients in the diet of inflammatory bowel diseases patients and the risk of osteoporosis. Nutrients. 2021;13(2):525.","journal-title":"Nutrients"},{"key":"3595_CR11","first-page":"000333","volume":"7","author":"TE Howe","year":"2011","unstructured":"Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;7:000333.","journal-title":"Cochrane Database Syst Rev"},{"key":"3595_CR12","doi-asserted-by":"crossref","unstructured":"Pharmacotherapy for postmenopausal osteoporosis. JAMA. 2021;325(18):1888\u20131889.","DOI":"10.1001\/jama.2020.13841"},{"issue":"1","key":"3595_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2020.2923","volume":"325","author":"KE Ensrud","year":"2021","unstructured":"Ensrud KE. Bisphosphonates for postmenopausal osteoporosis. JAMA. 2021;325(1):96.","journal-title":"JAMA"},{"issue":"8","key":"3595_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"3595_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1\u201323.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3595_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41574-020-00426-5","volume":"17","author":"EG Estell","year":"2021","unstructured":"Estell EG, Rosen CJ. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol. 2021;17(1):31\u201346.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"3595_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajhp\/zxy022","volume":"76","author":"A Sleeman","year":"2019","unstructured":"Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis. Am J Health Syst Pharm. 2019;76(3):130\u20135.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"3595_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA. Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157(1):141\u20139.","journal-title":"Endocrinology"},{"issue":"2","key":"3595_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1060028018798034","volume":"53","author":"QA Le","year":"2019","unstructured":"Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother. 2019;53(2):134\u201343.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3595_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M19-0533","volume":"171","author":"HA Fink","year":"2019","unstructured":"Fink HA, MacDonald R, Forte ML, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med. 2019;171(1):37\u201350.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3595_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722\u201333.","journal-title":"JAMA"},{"issue":"2","key":"3595_CR22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O\u2019Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3595_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40261-021-01008-7","volume":"41","author":"PD Miller","year":"2021","unstructured":"Miller PD, Troy S, Weiss RJ, et al. Phase 1b evaluation of abaloparatide solid microstructured transdermal system (Abaloparatide-sMTS) in postmenopausal women with low bone mineral density. Clin Drug Investig. 2021;41(3):277\u201385.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"3595_CR24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000001080","volume":"25","author":"MR McClung","year":"2018","unstructured":"McClung MR, Harvey NC, Fitzpatrick LA, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause. 2018;25(7):767\u201371.","journal-title":"Menopause"},{"issue":"6","key":"3595_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.clinthera.2020.04.012","volume":"42","author":"KG Saag","year":"2020","unstructured":"Saag KG, Williams SA, Wang Y, et al. Effect of abaloparatide on bone mineral density and fracture incidence in a subset of younger postmenopausal women with osteoporosis at high risk for fracture. Clin Ther. 2020;42(6):1099\u2013107.","journal-title":"Clin Ther"},{"issue":"1","key":"3595_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.2991","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Hattersley G, Hu MY, et al. Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res. 2017;32(1):17\u201323.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"3595_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jbmr.3163","volume":"32","author":"EV McCloskey","year":"2017","unstructured":"McCloskey EV, Johansson H, Oden A, et al. The effect of Abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res. 2017;32(8):1625\u201331.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"3595_CR28","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00198-019-04890-2","volume":"30","author":"NB Watts","year":"2019","unstructured":"Watts NB, Hattersley G, Fitzpatrick LA, et al. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2019;30(6):1187\u201394.","journal-title":"Osteoporos Int"},{"issue":"2","key":"3595_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200\u201310.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"3595_CR30","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949\u20131957.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3595_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14656566.2017.1418857","volume":"19","author":"JY Reginster","year":"2018","unstructured":"Reginster JY, Al Daghri N, Kaufman JM, et al. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Expert Opin Pharmacother. 2018;19(2):159\u201361.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"3595_CR32","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1210\/clinem\/dgz162","volume":"105","author":"BZ Leder","year":"2020","unstructured":"Leder BZ, Mitlak B, Hu MY, et al. Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2020;105(3):938\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3595_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00223-018-0450-0","volume":"103","author":"JY Reginster","year":"2018","unstructured":"Reginster JY, Hattersley G, Williams GC, et al. Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with teriparatide. Calcif Tissue Int. 2018;103(5):540\u20135.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"3595_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11657-019-0564-7","volume":"14","author":"EV McCloskey","year":"2019","unstructured":"McCloskey EV, Fitzpatrick LA, Hu MY, et al. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos. 2019;14(1):15.","journal-title":"Arch Osteoporos"},{"issue":"3","key":"3595_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00198-018-04819-1","volume":"30","author":"R Eastell","year":"2019","unstructured":"Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int. 2019;30(3):667\u201373.","journal-title":"Osteoporos Int"},{"key":"3595_CR36","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. 2006;1\u201310."},{"issue":"11","key":"3595_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","volume":"5","author":"R Eastell","year":"2017","unstructured":"Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3595_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/bmb\/ldac017","volume":"143","author":"F Migliorini","year":"2022","unstructured":"Migliorini F, Colarossi G, Eschweiler J, Oliva F, Driessen A, Maffulli N. Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis. Br Med Bull. 2022;143(1):46\u201356.","journal-title":"Br Med Bull"},{"issue":"1","key":"3595_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res. 2021;16(1):533.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"3595_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/17512433.2021.1851192","volume":"14","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Colarossi G, Baroncini A, Eschweiler J, Tingart M, Maffulli N. Pharmacological management of postmenopausal osteoporosis: a level i evidence based - expert opinion. Expert Rev Clin Pharmacol. 2021;14(1):105\u201319.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"3595_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S2213-8587(17)30178-X","volume":"5","author":"J Compston","year":"2017","unstructured":"Compston J. Safety of long-term denosumab therapy for osteoporosis. Lancet Diabetes Endocrinol. 2017;5(7):485\u20137.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3595_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmbbm.2020.104140","volume":"113","author":"J Mart\u00ednez-Reina","year":"2020","unstructured":"Mart\u00ednez-Reina J, Calvo-Gallego JL, Pivonka P. Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis. J Mech Behav Biomed Mater. 2020;113: 104140.","journal-title":"J Mech Behav Biomed Mater"},{"key":"3595_CR43","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bcp.2019.05.024","volume":"166","author":"S Bhattacharyya","year":"2019","unstructured":"Bhattacharyya S, Pal S, Chattopadhyay N. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol. 2019;166:185\u201391.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"3595_CR44","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res. 2022;37(8):1437\u201345.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"3595_CR45","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","volume":"35","author":"JP Bilezikian","year":"2019","unstructured":"Bilezikian JP, Hattersley G, Mitlak BH, et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Curr Med Res Opin. 2019;35(12):2097\u2013102.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3595_CR46","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13018-021-02474-7","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Spiezia F, Tingart M, Maria PG, Riccardo G. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021;16(1):318.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"3595_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13018-021-02497-0","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Spiezia F, Peretti GM, Tingart M, Giorgino R. Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021;16(1):351.","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"3595_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11914-021-00663-1","volume":"19","author":"F Cosman","year":"2021","unstructured":"Cosman F, Dempster DW. Anabolic agents for postmenopausal osteoporosis: how do you choose? Curr Osteoporos Rep. 2021;19(2):189\u2013205.","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"3595_CR49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00223-017-0375-z","volume":"102","author":"MR McClung","year":"2018","unstructured":"McClung MR, Williams GC, Hattersley G, Fitzpatrick LA, Wang Y, Miller PD. Geography of fracture incidence in postmenopausal women with osteoporosis treated with abaloparatide. Calcif Tissue Int. 2018;102(6):627\u201333.","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"3595_CR50","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465\u201373.","journal-title":"Osteoporos Int"},{"issue":"6","key":"3595_CR51","first-page":"2640","volume":"23","author":"L Yang","year":"2019","unstructured":"Yang L, Kang N, Yang JC, Su QJ, Liu YZ, Guan L, Liu T, Meng XL, Wang Y, Hai Y. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(6):2640\u201368.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3595_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","volume":"129","author":"AV Hernandez","year":"2019","unstructured":"Hernandez AV, P\u00e9rez-L\u00f3pez FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Maturitas. 2019;129:12\u201322.","journal-title":"Maturitas"},{"issue":"8","key":"3595_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/GME.0000000000001321","volume":"26","author":"X Tan","year":"2019","unstructured":"Tan X, Wen F, Yang W, Xie JY, Ding LL, Mo YX. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). Menopause. 2019;26(8):929\u201339.","journal-title":"Menopause"},{"issue":"12","key":"3595_CR54","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M. Abaloparatide: first global approval. Drugs. 2017;77(12):1363\u20138.","journal-title":"Drugs"},{"issue":"7","key":"3595_CR55","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465\u201373.","journal-title":"Osteoporos Int"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-023-03595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-023-03595-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-023-03595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T06:04:43Z","timestamp":1676613883000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-023-03595-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3595"],"URL":"https:\/\/doi.org\/10.1186\/s13018-023-03595-x","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}